Mayo Clinic Joins Federal AEGIS Initiative to Develop Gene-Editing Cures for Rare Immune Disorders

When we look at the landscape of inborn errors of immunity in our pediatric immunology clinics, the numbers are striking: more than 500 rare genetic disorders fall under this umbrella, many of them with limited treatment options and no cure. That is why the news from Mayo Clinic — reported via Newswise this week — carries real weight for the families and clinicians navigating these conditions every day.

What the AEGIS program is built around

Mayo Clinic has joined a five-year, federally backed initiative called AEGIS, anchored by an ARPA-H award of up to $27.7 million. The project is led by the Innovative Genomics Institute at the University of California, Berkeley, and brings together a consortium of academic, clinical, nonprofit and industry partners. At its core, AEGIS combines CRISPR-based gene editing with new manufacturing and delivery approaches, aiming to create one-time therapies that repair disease-causing errors in blood-forming stem cells — the precursors of the immune system — and restore normal immune function rather than simply manage symptoms over a lifetime.

Why Mayo's role matters for pediatric patients

Mayo will serve as one of three clinical sites within the program's planned clinical trials, helping to identify, enroll and care for children who may benefit from these investigational therapies. Dr. Avni Joshi, chair of Mayo Clinic's Division of Pediatric Allergy and Immunology and the project's lead principal investigator at Mayo, put the clinical vision directly: "By combining advances in gene editing with new ways to deliver treatments, we hope to create therapies that not only treat disease but address its root cause. Our goal is to free patients from the burden of ongoing treatments, and ultimately improve the lives of patients and families."

What makes Mayo's seat at the table practical rather than symbolic is its existing clinical infrastructure. Mayo is a member of the Primary Immune Deficiency Treatment Consortium and a FACT-accredited transplant center, with established expertise in pediatric transplantation and in advanced cellular and gene therapies. That combination of consortium access, transplant capability and hands-on experience with rare immune disorders is precisely what allows a research program like AEGIS to translate from a laboratory framework into actual bedside care for children.

What to track in the coming months

The consortium spans researchers and clinicians from UCLA, Stanford, the University of Utah, Princeton, UC San Diego, Emory, Danaher Corporation, the Immune Deficiency Foundation and other partners, and the work aligns with ARPA-H's THRIVE program — an effort explicitly focused on expanding access to transformative genetic medicines. For clinicians counseling families and for parents of children living with inborn errors of immunity, the practical markers to follow are concrete: which specific conditions AEGIS prioritizes in its first wave, when the first pediatric trial opens at Mayo, and how the scalable manufacturing framework performs over time, since affordability and broad reach are part of the program's stated mission from day one.